Skip to main content
Equibles
TMDX logo

TMDX · TransMedics Group, Inc. · Metrics

Track TMDX — free

Use TMDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$74.75 +3.15 (+4.40%) At close · Oct 20
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.48B
Shares
34.68M
Volume · Oct 20 1.17M Avg daily vol (3M) 835.45K

TMDX metrics

98 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$74.75
Market cap
$2.48B

Price action

20 metrics
Price change (1W)
-5.5%
Price change (30D)
-14.4%
Price change (3M)
+0.6%
Price change (6M)
-31.4%
Price change (YTD)
-38.6%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
+177.9%
52-week high
$150.42
52-week low
$62.04
Change from 52-week high
-50.3%
Change from 52-week low
+20.5%
Annualized volatility
57.6%
Annualized volatility (3M)
48.0%
Beta
1.1
RSI (14D)
40.4
Price vs SMA 50
-12.0%
Price vs SMA 200
-23.1%
Avg volume (3M)
835,447
Relative volume
1.4
Average dollar volume
$68.69M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
34.68M

Valuation

12 metrics
P / E (TTM)
19.4
Trailing earnings · reciprocal yield 5.2%
PEG ratio
—
EV / revenue
4.3×
reciprocal yield 23.4%
EV / EBITDA
24.2×
reciprocal yield 4.1%
EV / EBIT
35.0×
reciprocal yield 2.9%
P / sales
3.7×
reciprocal yield 26.9%
P / book
4.8
reciprocal yield 20.9%
FCF yield
3.2%
TTM · current market cap
Buyback yield
—
P / FCF
31.4
reciprocal yield 3.2%
P / operating cash flow
17.0
reciprocal yield 5.9%
Earnings yield
6.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
16.6×
reciprocal yield 6.0%
EV / revenue historical average (5Y)
15.9×
reciprocal yield 6.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
58.7%
Operating margin
12.2%
Trailing 12 months
Net margin
22.7%
Gross profit (TTM)
$392.35M
Operating profit (TTM)
$81.61M
Net income (TTM)
$151.70M
Trailing 12 months
Diluted EPS (TTM)
$3.86
FCF margin
11.8%
Effective tax rate
-109.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$16.93
Gross profit per diluted share (TTM)
$9.93
Operating profit per diluted share (TTM)
$2.04
EBITDA per diluted share (TTM)
$2.97
Net income per diluted share (TTM)
$3.73
Operating cash flow per diluted share (TTM)
$3.65
Free cash flow per diluted share (TTM)
$1.90
Capital expenditures per diluted share (TTM)
$1.75
R&D per diluted share (TTM)
$2.34
Stock compensation per diluted share (TTM)
$0.94
Book value per share
$13.81

Growth

11 metrics
Revenue growth YoY
+20.7%
Year over year
Net income growth YoY
-57.9%
Revenue (TTM)
$668.47M
Trailing 12 months
EPS growth YoY
-55.4%
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
+86.4%
Revenue CAGR (5Y)
+88.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
29.3%
Return on assets
10.4%
Debt / equity
1.7
Current ratio
6.6
EBITDA (TTM)
$118.03M
Free cash flow (TTM)
$79.04M
Quick ratio
6.1
Interest coverage
3.8
Net debt / EBITDA
3.1
Return on invested capital
—
Trailing 12 months
Net cash
−$370.55M
Latest balance sheet
Cash & equivalents
$491.11M
Total assets
$1.46B
Total debt
$861.66M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$145.93M
Capital expenditures (TTM)
$66.89M
R&D (TTM)
$92.47M
SG&A (TTM)
$218.27M
Stock compensation (TTM)
$37.09M
R&D / revenue
13.8%
Stock compensation / revenue
5.5%

Ownership (13F)

9 metrics
13F filers
382
13F filer change QoQ
-38
Institutional ownership
109.9%
Conviction holders (share of 13F filers)
0.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-4.2%
Holder tenure
14.1
Price vs estimated holder cost
-29.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
28.3%

Short interest

3 metrics
Short interest
24.7%
Latest settlement · 13.1 days to cover
Days to cover
13.1d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
$109,058
Insider-sentiment score
78 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1756262 CUSIP 89377M109 13F (30d) 53 filings 53 filers Visit website Investor relations